Skip to main content
Top
Published in: Cancer Causes & Control 8/2014

01-08-2014 | Original paper

Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening

Authors: Dolores Salas, Mercedes Vanaclocha, Josefa Ibáñez, Ana Molina-Barceló, Vicente Hernández, Joaquín Cubiella, Raquel Zubizarreta, Montserrat Andreu, Cristina Hernández, Francisco Pérez-Riquelme, José Cruzado, Fernando Carballo, Luis Bujanda, Cristina Sarasqueta, Isabel Portillo, Mariola de la Vega-Prieto, Juan Diego Morillas, Vicente Valentín, Ángel Lanas, Enrique Quintero, Antoni Castells

Published in: Cancer Causes & Control | Issue 8/2014

Login to get access

Abstract

Purpose

To compare two strategies for colorectal cancer screening: one-time colonoscopy versus fecal immunochemical testing (FIT) (and colonoscopy for positive) every 2 years, in order to determine which strategy provides the highest participation and detection rates in groups of sex and age.

Methods

This analysis was performed with data from the first screening round within the COLONPREV study, a population-based, multicenter, nationwide trial carried out in Spain. Several logistic regression models were applied to identify the influence of the screening test on participation rates and detection of proximal and distal neoplasms, as well to identify the influence of age and sex: women aged 50–59 years, women aged 60–69 years, men aged 50–59 years, and men aged 60–69 years.

Results

Participation was higher in women than in men, especially among women aged 50–59 years (25.91 % for colonoscopy and 35.81 % for FIT). Crossover from colonoscopy to FIT was higher among women than men, especially among those aged 60–69 years (30.37 %). In general, detection of any neoplasm and advanced adenoma was higher with colonoscopy than with FIT, but no significant differences were found between the two strategies for colorectal cancer detection. Detection of advanced adenoma in both arms was lower in women [specifically in women aged 50–59 years (OR 0.31; 95 % CI 0.25–0.38) than in men aged 60–69 years]. Women aged 50–59 years in the colonoscopy arm had a higher probability of detection of advanced adenoma (OR 4.49; 95 % CI 3.18–6.35), as well as of detection of neoplasms in proximal and distal locations (proximal OR 19.34; 95 % CI 12.07–31.00; distal OR 11.04; 95 % CI 8.13–15.01) than women of the same age in the FIT arm. These differences were also observed in the remaining groups but to a lesser extent.

Conclusion

Women were more likely to participate in a FIT-based strategy, especially those aged 50–59 years. The likelihood of detection of any neoplasm was higher in the colonoscopy arm for all the population groups studied, especially in women aged 50–59 years. Distinct population groups should be informed of the benefits of each screening strategy so that they may take informed decisions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ, American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595 Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ, American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595
2.
go back to reference Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343(22):1603–1607PubMedCrossRef Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343(22):1603–1607PubMedCrossRef
3.
go back to reference Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103(6):1541–1549PubMedCrossRef Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103(6):1541–1549PubMedCrossRef
4.
go back to reference Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726):1624–1633PubMedCrossRef Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726):1624–1633PubMedCrossRef
5.
go back to reference Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 15(4):163–174PubMedCrossRef Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 15(4):163–174PubMedCrossRef
6.
go back to reference von Wagner C, Good A, Wright D, Rachet B, Obichere A, Bloom S, Wardle J (2009) Inequalities in colorectal cancer screening participation in the first round of the national screening programme in England. Br J Cancer 3(101 Suppl 2):S60–S63CrossRef von Wagner C, Good A, Wright D, Rachet B, Obichere A, Bloom S, Wardle J (2009) Inequalities in colorectal cancer screening participation in the first round of the national screening programme in England. Br J Cancer 3(101 Suppl 2):S60–S63CrossRef
7.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN
8.
go back to reference Brasso K, Lynge E (2010) Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health (Oxf) 32(3):395–405CrossRef Brasso K, Lynge E (2010) Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health (Oxf) 32(3):395–405CrossRef
9.
go back to reference Wardle J, Miles A, Atkin W (2005) Gender differences in utilization of colorectal cancer screening. J Med Screen 12(1):20–27PubMedCrossRef Wardle J, Miles A, Atkin W (2005) Gender differences in utilization of colorectal cancer screening. J Med Screen 12(1):20–27PubMedCrossRef
10.
go back to reference Javanparast S, Ward P, Young G, Wilson C, Carter S, Misan G, Cole S, Jiwa M, Tsourtos G, Martini A, Gill T, Baratiny G, Matt MA (2010) How equitable are colorectal cancer screening programs which include FOBTs? A review of qualitative and quantitative studies. Prev Med 50(4):165–172PubMedCrossRef Javanparast S, Ward P, Young G, Wilson C, Carter S, Misan G, Cole S, Jiwa M, Tsourtos G, Martini A, Gill T, Baratiny G, Matt MA (2010) How equitable are colorectal cancer screening programs which include FOBTs? A review of qualitative and quantitative studies. Prev Med 50(4):165–172PubMedCrossRef
11.
go back to reference Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E, Borgia P, Zullo A, Guasticchi G, HTA Group (2012) Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 36(10):929–940PubMedCrossRef Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E, Borgia P, Zullo A, Guasticchi G, HTA Group (2012) Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 36(10):929–940PubMedCrossRef
12.
go back to reference Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ (2010) Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59(1):62–68PubMedCrossRef Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ (2010) Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59(1):62–68PubMedCrossRef
13.
go back to reference Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M, SCORE3 Working Group-Italy (2007) Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 132(7):2304–2312PubMedCrossRef Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M, SCORE3 Working Group-Italy (2007) Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 132(7):2304–2312PubMedCrossRef
14.
go back to reference Lieberman D (2009) Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 25(5):422–427PubMedCrossRef Lieberman D (2009) Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 25(5):422–427PubMedCrossRef
15.
go back to reference Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT (2013) Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369(12):1095–1105PubMedCrossRef Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT (2013) Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369(12):1095–1105PubMedCrossRef
16.
go back to reference Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A, COLONPREV Study Investigators (2012) Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366(8):697–706PubMedCrossRef Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A, COLONPREV Study Investigators (2012) Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366(8):697–706PubMedCrossRef
17.
go back to reference Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchén P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradesanferm A, Soriano Izquierdo A, Vázquez Sequeiros E, Spanish Society of Gastroenterology, Spanish Society of Gastrointestinal Endoscopy Working Group (2012) Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44(4):444–451PubMedCrossRef Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchén P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradesanferm A, Soriano Izquierdo A, Vázquez Sequeiros E, Spanish Society of Gastroenterology, Spanish Society of Gastrointestinal Endoscopy Working Group (2012) Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44(4):444–451PubMedCrossRef
18.
go back to reference Pox CP, Altenhofen L, Brenner H, Theilmeier A, Von Stillfried D, Schmiegel W (2012) Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142(7):1460–1467PubMedCrossRef Pox CP, Altenhofen L, Brenner H, Theilmeier A, Von Stillfried D, Schmiegel W (2012) Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142(7):1460–1467PubMedCrossRef
19.
go back to reference Wong MC, John GK, Hirai HW, Lam TY, Luk AK, Ching JY, Ng SS, Chan FK, Griffiths SM, Sung JJ (2012) Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys. Cancer Causes Control 23(9):1541–1548PubMedCrossRef Wong MC, John GK, Hirai HW, Lam TY, Luk AK, Ching JY, Ng SS, Chan FK, Griffiths SM, Sung JJ (2012) Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys. Cancer Causes Control 23(9):1541–1548PubMedCrossRef
20.
go back to reference Senore C, Ederle A, Benazzato L, Arrigoni A, Silvani M, Fantin A, Fracchia M, Armaroli P, Segnan N (2013) Offering people a choice for colorectal cancer screening. Gut 62(5):735–740PubMedCrossRef Senore C, Ederle A, Benazzato L, Arrigoni A, Silvani M, Fantin A, Fracchia M, Armaroli P, Segnan N (2013) Offering people a choice for colorectal cancer screening. Gut 62(5):735–740PubMedCrossRef
21.
go back to reference Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR (2009) Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 7(12):1272–1278PubMedCrossRef Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR (2009) Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 7(12):1272–1278PubMedCrossRef
22.
go back to reference Lieberman DA, Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, Schnell TG, Chejfec G, Campbell DR, Kidao J, Bond JH, Nelson DB, Triadafilopoulos G, Ramirez FC, Collins JF, Johnston TK, McQuaid KR, Garewal H, Sampliner RE, Esquivel R, Robertson D (2007) Five-year colon surveillance after screening colonoscopy. Gastroenterology 133(4):1077–1085PubMedCrossRef Lieberman DA, Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, Schnell TG, Chejfec G, Campbell DR, Kidao J, Bond JH, Nelson DB, Triadafilopoulos G, Ramirez FC, Collins JF, Johnston TK, McQuaid KR, Garewal H, Sampliner RE, Esquivel R, Robertson D (2007) Five-year colon surveillance after screening colonoscopy. Gastroenterology 133(4):1077–1085PubMedCrossRef
23.
go back to reference Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF (2012) Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med 125(12):1181–1187PubMedCentralPubMedCrossRef Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF (2012) Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med 125(12):1181–1187PubMedCentralPubMedCrossRef
24.
go back to reference Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012) High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10(6):633–638PubMedCrossRef Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012) High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10(6):633–638PubMedCrossRef
Metadata
Title
Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening
Authors
Dolores Salas
Mercedes Vanaclocha
Josefa Ibáñez
Ana Molina-Barceló
Vicente Hernández
Joaquín Cubiella
Raquel Zubizarreta
Montserrat Andreu
Cristina Hernández
Francisco Pérez-Riquelme
José Cruzado
Fernando Carballo
Luis Bujanda
Cristina Sarasqueta
Isabel Portillo
Mariola de la Vega-Prieto
Juan Diego Morillas
Vicente Valentín
Ángel Lanas
Enrique Quintero
Antoni Castells
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 8/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0398-y

Other articles of this Issue 8/2014

Cancer Causes & Control 8/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine